TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07371624: A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Adipose-Derived Mesenchymal Stromal Cell Injection (B2065) in Participants With Acute Ischemic Stroke.

Sponsor: Tasly Pharmaceutical Group Co., Ltd · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07371624 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07371624 Rescue Dossier →